HDL: moving forward after disappointing results with HDL-mimetic in CARAT study.
Prof. Stephen Nicholls indicates that because of the very different therapeutic approaches with respect to HDL, therapies still move forward, despite agents failing to demonstrate benefit. The HDL mimetic CER-001, on top of a statin, showed no effect on plaque regression in post-ACS patients.
Video navigation menu
- CARAT: No effect of CER-001 on plaque regression in post-ACS patients on top of statin 00:35
- Where does this leave the HDL world? 01:28
- HDL is not as simple as LDL 03:06
This video was recorded during ACC 2017, Washington DC, USA. PACE-cme did not receive financial support for the production of this video.
The educational content reflects the personal opinion of the expert.
Stephen J. Nicholls, MD, PhD, is Professor of Cardiology and Theme Leader at the South Australian Health & Medical Research Institute (SAHMRI) in Adelaide, Australia.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: